专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09539209B2 Vaccine for mycoplasma infection 有权
标题翻译：疫苗支原体感染
公开(公告)号：US09539209B2
公开(公告)日：2017-01-10
申请号：US13376009
申请日：2010-06-04
申请人： Kazuhiro Matsuda , Koji Ichiyama , Sachie Matsuda , Yuko Sasaki , Yoshichika Arakawa , Ryo Harasawa , Yoshihiro Nishida , Norio Katayama , Yasuo Endo , Nobuo Nomura
发明人： Kazuhiro Matsuda , Koji Ichiyama , Sachie Matsuda , Yuko Sasaki , Yoshichika Arakawa , Ryo Harasawa , Yoshihiro Nishida , Norio Katayama , Yasuo Endo , Nobuo Nomura
IPC分类号： A61K39/02 , A61K39/00 , A61K49/00 , A61K9/127 , A61K39/39 , A61K39/145 , A61K39/12
CPC分类号： A61K39/0241 , A61K9/127 , A61K9/1272 , A61K39/12 , A61K39/145 , A61K39/39 , A61K2039/55555 , A61K2039/55594 , Y02A50/403
摘要： Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
摘要翻译：公开了对支原体感染具有高治疗效果的疫苗，并且是高度安全的。为了开发有效的支原体感染治疗方法，提供了作为支原体感染疫苗有效的支原体模拟颗粒，并且还提供了包括常见细菌的细菌模拟颗粒。可以通过生产脂质体颗粒来提供细菌模拟颗粒，例如支原体模拟颗粒，其中作为构成脂质体的脂质组分含有诸如支原体的致病菌特异性的脂质抗原。支原体模拟颗粒的施用使得能够诱导活体中有效的免疫活性。支原体模拟颗粒可用作预防或治疗支原体感染的优良疫苗。

2. 发明授权

US06456182B1 Common mode choke coil 失效
标题翻译：共模扼流圈
公开(公告)号：US06456182B1
公开(公告)日：2002-09-24
申请号：US09518273
申请日：2000-03-03
申请人： Norio Katayama , Toshinori Okamoto
发明人： Norio Katayama , Toshinori Okamoto
IPC分类号： H01F2734
CPC分类号： H01F27/324 , H01F3/10 , H01F3/14 , H01F17/062 , H01F27/33 , H01F27/34
摘要： In a common mode choke coil, a closed magnetic circuit core (2) is divided in parallel with its magnetic circuit, and formed by superimposing together for integration a first divided magnetic core (2a), a second divided magnetic core (2b) and a third divided magnetic core (2c) which are made of an oxide magnetic substance having the high permeability. Since the closed magnetic circuit core (2) is made of the oxide magnetic substance having the high permeability, the impedance in the low frequency band (10 kHz side) is large. Also, since the sectional area of the closed magnetic circuit core (2) (divided magnetic core) is set to be small, the permeability in the high frequency band (10 MHz side) becomes high due to the dimensional resonance phenomenon, and then the impedance also becomes large. For that reason, the noise in the wide frequency band of 10 kHz to 10 MHz can sufficiently be attenuated.
摘要翻译：在共模扼流线圈中，封闭磁路铁心（2）与其磁路并联分开，并通过叠加在一起形成第一分割磁芯（2a），第二分割磁芯（2b）和第三分割磁芯（2c），其由具有高磁导率的氧化物磁性物质制成。由于闭磁回路芯（2）由具有高磁导率的氧化物磁性体制成，所以低频带（10kHz侧）的阻抗较大。此外，由于封闭磁路铁心（2）（分割磁芯）的截面积设定得较小，所以由于尺寸共振现象，高频带（10MHz侧）的磁导率变高，阻抗也变大。因此，可以充分地衰减10kHz至10MHz的宽频带中的噪声。

3. 发明申请

US20120135067A1 VACCINE FOR MYCOPLASMA INFECTION 有权
标题翻译：疫苗用于感染MYCOPLASMA
公开(公告)号：US20120135067A1
公开(公告)日：2012-05-31
申请号：US13376009
申请日：2010-06-04
申请人： Kazuhiro Matsuda , Koji Ichiyama , Sachie Matsuda , Yuko Sasaki , Yoshichika Arakawa , Ryo Harasawa , Yoshihiro Nishida , Norio Katayama , Yasuo Endo , Nobuo Nomura
发明人： Kazuhiro Matsuda , Koji Ichiyama , Sachie Matsuda , Yuko Sasaki , Yoshichika Arakawa , Ryo Harasawa , Yoshihiro Nishida , Norio Katayama , Yasuo Endo , Nobuo Nomura
IPC分类号： A61K9/127 , A61P37/04 , A61K39/02 , A61K39/09 , A61P31/16 , A61P31/00 , A61P11/06 , A61P19/02 , A61P11/00 , A61K9/00 , A61K39/145
CPC分类号： A61K39/0241 , A61K9/127 , A61K9/1272 , A61K39/12 , A61K39/145 , A61K39/39 , A61K2039/55555 , A61K2039/55594 , Y02A50/403
摘要： Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
摘要翻译：公开了对支原体感染具有高治疗效果的疫苗，并且是高度安全的。为了开发有效的支原体感染治疗方法，提供了作为支原体感染疫苗有效的支原体模拟颗粒，并且还提供了包括常见细菌的细菌模拟颗粒。可以通过生产脂质体颗粒来提供细菌模拟颗粒，例如支原体模拟颗粒，其中作为构成脂质体的脂质组分含有诸如支原体的致病菌特异性的脂质抗原。支原体模拟颗粒的施用使得能够诱导活体中有效的免疫活性。支原体模拟颗粒可用作预防或治疗支原体感染的优良疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式